REDEFINING THE FUTURE OF INFECTIOUS DISEASE TREATMENT
We address the unmet need for new and improved treatment and diagnostics for infectious diseases. By combining innovative research, rapid development, and clinical insight, we aim to deliver solutions that improve patient outcomes and strengthen global health preparedness.
Impact
Combatting Invasive Fungal Pathogens Head-On
Vitalex is a pre-clinical-stage biotechnology startup dedicated to resolving critical unmet needs in infectious disease. By leveraging precision therapeutics and novel discovery platforms, we are pioneering targeted treatments for life-threatening fungal infections to improve global patient outcomes.
Our Pipeline
A catalog of our research and development results. With much more to come.
VX-01
Monoclonal antibody targeting CotH cell surface protein on Mucorales
VXV-01
A dual antigen vaccine targeting hospital-acquired infections caused by multidrug resistant Candida albicans, Candida auris, and Gram-negative bacteria
VXD-01
A rapid diagnostic test for Mucormycosis
Vitalex in the Press
Stay informed about some of our latest breakthroughs, milestones, and the ongoing progress of our programs.
Vitalex Biosciences Announces Strategic Advancement of Second-Generation fungal Vaccine VXV-01 through Phase 1 Trials under $40 Million Competitive Contract from NIH/NIAID